Neural markers of remission in first-episode schizophrenia: a volumetric neuroimaging study of the hippocampus and amygdala

Schizophrenia Research
Michael BodnarMartin Lepage

Abstract

The temporolimbic region has been implicated in the pathophysiology in schizophrenia. More specifically, significantly smaller hippocampal volumes but not amygdala volumes have been identified at onset in first-episode schizophrenia (FES) patients. However, volumetric differences (namely, in the hippocampus) exhibit an ambiguous relationship with long-term outcome. So, we examined the relationship between hippocampus and amygdala volumes and early remission status. We compared hippocampus and amygdala volumes between 40 non-remitted and 17 remitted FES patients and 57 healthy controls. Amygdala and hippocampus were manually traced with the hippocampus additionally segmented into three parts: body, head, and tail. Remission was defined as mild or less on both positive and negative symptoms over a period of 6 consecutive months as per the 2005 Remission in Schizophrenia Working Group criteria. A significant [group x structure x side] interaction revealed outcome groups differed in hippocampus tail volumes; significantly on the left (non-remitted=694+/-175 mm(3); remitted=855+/-133 mm(3); p=0.001) with a trend difference on the right (non-remitted=723+/-162 mm(3); remitted=833+/-126 mm(3); p=0.023). Groups did not differ in body, ...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Mar 1, 1994·Journal of Computer Assisted Tomography·D L CollinsA C Evans
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Jun 9, 1998·IEEE Transactions on Medical Imaging·J G SledA C Evans
Sep 7, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D GothelfA Weizman
Mar 21, 2001·Biological Psychiatry·J LiebermanR Bilder
Jun 5, 2001·The British Journal of Psychiatry : the Journal of Mental Science·G HarrisonD Wiersma
Aug 14, 2001·Journal of Analytical Toxicology·E A Stein
Feb 2, 2002·The American Journal of Psychiatry·Philip R SzeszkoRobert M Bilder
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Jul 23, 2003·The Australian and New Zealand Journal of Psychiatry·Ashok MallaLaurel Townsend
Nov 26, 2003·The American Journal of Psychiatry·Philip R SzeszkoRobert M Bilder
Jan 27, 2004·Schizophrenia Research·Marquis P VawterWilliam Byerley
Mar 3, 2004·The American Journal of Psychiatry·Delbert G RobinsonRobert M Bilder
Mar 31, 2004·NeuroImage·Katherine L NarrRobert M Bilder
Jun 29, 2004·Trends in Pharmacological Sciences·Garry Honey, Ed Bullmore
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Apr 28, 2005·Expert Review of Neurotherapeutics·Timothea Toulopoulouand, Robin M Murray
Sep 27, 2005·Cellular Signalling·Katherine B Hubbard, John R Hepler
Jun 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·R Grant SteenJeffrey A Lieberman
Sep 12, 2006·Journal of Psychiatric Research·Lars HelldinTrevor Archer
Mar 3, 2007·The British Journal of Psychiatry : the Journal of Mental Science·A Vita, L de Peri
Jul 3, 2007·Schizophrenia Research·Giuseppina RamettiMiguel Bernardo
Mar 12, 2008·Current Opinion in Psychiatry·Robin EmsleyRenata Schoeman
Sep 9, 2008·Acta Neuropathologica·Andrea SchmittPeter Falkai
Dec 3, 2008·Schizophrenia Research·J FitzsimmonsM E Shenton
Feb 17, 2009·Psychiatry Research·Giuseppina RamettiMiguel Bernardo
Feb 19, 2009·European Archives of Psychiatry and Clinical Neuroscience·Thomas WobrockPeter Falkai
Mar 20, 2009·The Australian and New Zealand Journal of Psychiatry·Maryam NesvaderaniSinthuja Sivagnanasundaram

❮ Previous
Next ❯

Citations

Mar 1, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Michael BodnarMartin Lepage
Apr 2, 2016·Psychiatry Research. Neuroimaging·Alyson M RichAlan Anticevic
Aug 30, 2012·The Psychiatric Clinics of North America·John G Kerns, John Lauriello
Jan 30, 2013·Early Intervention in Psychiatry·Tina C MontreuilMartin Lepage
Feb 27, 2015·The International Journal of Neuropsychopharmacology·Valerie M AndersonBruce R Russell
Dec 18, 2013·European Psychiatry : the Journal of the Association of European Psychiatrists·E JääskeläinenM Isohanni
Jul 13, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Martin HýžaTomáš Kašpárek
Feb 3, 2011·Current Opinion in Psychiatry·Robin EmsleyKeneilwa Lehloenya
Sep 3, 2020·Translational Psychiatry·Maureen McHugoStephan Heckers
Dec 6, 2019·Frontiers in Psychiatry·Jeong-Youn KimYoung-Chul Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.